7th Annual Pharma Pricing, Reimbursement & Market Access 2023

7th Annual Pharma Pricing, Reimbursement & Market Access 2023 is organized by Virtue Insight and will be held from May 24 - 25, 2023 at The Conference Center at Waltham Woods, Waltham, Massachusetts, United States of America.

Description:
This conference will provide an overview of global pharma pricing, market access systems and cost management techniques, as well as in-depth discussion of some of the most current trends and changes. This conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. It will be studied with the help of case studies and industry experiences. Following a raft of health policy reforms impacting pharmaceutical pricing in almost every major country in the EU, it gives me great pleasure in welcoming all of you to the Virtue Insight’s 7th Annual Pharma Pricing, Reimbursement & Market Access 2023.

Pricing and market access (P&MA) are key concerns for the pharma industry as healthcare budgets remain to tighten and the value of advanced drugs, particularly in areas of high unmet need, becomes infinitely solider to assess. Pharma and payers are forceful to find a balance between budget management and patient access. Pricing has consistently been a pressure point.
This is even more risky today with the shift to specialty products and treatment of rare diseases. As P&MA becomes central to commercialization, P&MA as a function is crucial to achieving leadership through this challenging environment. However, it is vital that we not just identify trends – but as an industry we stay ahead of them and even influence their evolution. P&MA
cannot be just a source of expertise within pharma – it needs to be an active leader of business results, shaping the future and engaging with stakeholders, and influencing decision-making.

Key Themes Discussed in This Conference:
Implications for companies – What to Prepare for 2025?
• Pharma pricing and market access in the US: From Dream to Reality
• The new normal: HTA & Reimbursement challenges in a post-pandemic world
• Prioritising Prioritizing patient-centred care
• The rise of digital health and value-based healthcare
• Implementing a pricing and market access strategy
• HTA and decision making in the reimbursement of medicines
• Payer’s perspective – What are they looking for?
• Importance of working together - Stakeholders- Industry, Payers, Physicians & Patients
• Evidence Generation - The strategic rigor and creativity applied to evidence generation
• Developing risk-sharing reimbursement models and value-based pricing
• The international pricing system
• Integrating real-world data into pricing
• Patient engagement and adherence within the environment
• Adding value through an innovative patient-centred approach
• Robust patient services & reimbursement support program for biosimilar products
• Recent regulatory updates & development